pharma · Myotonic Dystrophy Type 1 · Myotonic Dystrophy Type 1 (DM1) · DYN
Dyne Therapeutics
Dyne Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker DYN. Primary therapeutic focus areas include Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 1 (DM1), Duchenne m
Waltham, USA HQ
2018 Founded
276 Employees
Public company Type
DYN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2018
- Employees
- 276
- Programs
- 6
- Drugs
- 11
- Patents
- 82
zeleciment basivarsen (DYNE-101)
Phase 3 · small molecule · Myotonic Dystrophy Type 1 (DM1)
zeleciment basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) is a Phase 3 program (small_molecule) at Dyne Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code DYNE101-DM1-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dyne Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Myotonic Dystrophy Type 1 (DM1)
- Status
- active
- Trials
- 1